Q&A: Pegloticase sustained lower serum urate in kidney transplant recipients with gout

Among kidney transplant recipients with uncontrolled gout, pegloticase showed sustained decreased serum urate levels, according to findings presented at the American Transplant Congress.
Patients also showed pain relief and decreased disability without worsening kidney function.
Gout can be severe among kidney transplant recipients due to their decreased renal urate excretion, but pegloticase can rapidly metabolize urate. In this study, researchers administered 8 mg of pegloticase to patients every 2 weeks in addition to gout flare prophylaxis. Overall, 14 kidney transplant recipients with

Among kidney transplant recipients with uncontrolled gout, pegloticase showed sustained decreased serum urate levels, according to findings presented at the American Transplant Congress.
Patients also showed pain relief and decreased disability without worsening kidney function.
Gout can be severe among kidney transplant recipients due to their decreased renal urate excretion, but pegloticase can rapidly metabolize urate. In this study, researchers administered 8 mg of pegloticase to patients every 2 weeks in addition to gout flare prophylaxis. Overall, 14 kidney transplant recipients with